Business
Business update and notice of interim results
Business update and notice of interim results.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n RNS Number : 5456N\n Oxford BioDynamics PLC\n 21 May 2020\n \n \n \n \n 21 May 2020\n \n \n Oxford BioDynamics Plc\n \n \n (\n \"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \n \n \n \n \n Business update and notice of interim results \n \n \n Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch™, expects to announce its interim results for the half-year ended 31 March 2020 on 16 June 2020.\n \n The Group also provides an update on the actions it is taking in response to the COVID-19 pandemic. The Group remains in a strong position and is pleased to be playing a role in the fight against the coronavirus.\n \n Trading update and response to COVID-19\n OBD was pleased to announce on 30 April its involvement in the Chief Scientist Office of Scotland-funded GETAFIX clinical study alongside Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland. The Group's Episwitch™ technology was chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the study. Our contribution to this important study will be a priority, along with ongoing work on existing projects, over the coming few months.\n \n The Group's newly-appointed Chief Executive Officer, Dr Jon Burrows, joined the Company in late March. Jon has been working closely with OBD's senior executives to position the Group to be ready to benefit from the adoption of its unique and valuable technology platform, EpiSwitch™, by a growing customer base.\n \n The COVID-19 pandemic has already had an impact, which is expected to continue, on the timing of certain existing projects, directly as a result of delays in receipt of blood samples, especially from cohorts of patients who are considered particularly vulnerable to serious illness from a COVID-19 infection. In addition, travel restrictions worldwide have impacted business development activity. The likely severity and duration of the pandemic and its impact on OBD's customers' activities remains uncertain. In light of the open-ended nature of the crisis and associated impact on the Company's operations, the Board is ...